Structure-based classification predicts drug response in EGFR-mutant NSCLC—Nature
"One of the most important journal articles written in this field--
Bravo to Jacqulyne Ponville Robichaux, PhD, John Heymach,MD, PhD, and members of the John V. Heymach Laboratory at
The University of Texas MD Anderson Cancer Center."—Marcia K. Horn, JD
FDA Approves Mobocertinib for NSCLC with EGFR Exon 20 Insertion Mutations—Oncology Nursing News
"As a patient advocate working with EGFR Exon20 insertion+ NSCLC patients and their families every day for nearly five years, I am thrilled to witness continued progress in the fight against this devastating disease and am grateful for the patients, families, healthcare professionals and scientists across the globe who contributed to the approval of this promising targeted therapy." —Marcia Horn, executive director, Exon 20 Group at ICAN, International Cancer Advocacy Network.